{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-020636","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2022-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.337029+00:00","generated_at":"2026-06-22T21:40:25.460635+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Corbus Pharmaceuticals amends loan agreement, defers principal payments, adjusts conversion prices on $2M of debt","bullets":["Principal repayments deferred from Sept 2022 to Sept 2023; if Co. raises ≥$30M, extended to March 2024.","Conversion price on $875K debt lowered to $0.15/share, $1.125M to $0.2625/share (from $9.40).","Company paid $100K at amendment and will pay $400K at loan maturity.","Lenders refunded Sept & Oct 2022 principal payments already made."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-020636","json":"https://secwatch.observer/filing/0000950170-22-020636.json","markdown":"https://secwatch.observer/filing/0000950170-22-020636.md","text":"https://secwatch.observer/filing/0000950170-22-020636.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017022020636/0000950170-22-020636-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017022020636/crbp-20221025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T21:40:25.460635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"390dd5be0034700f09d834fc6c1616fb9b02b521","claim":"Corbus Pharmaceuticals Holdings, Inc. amended Amended Loan Agreement with K2 HealthVentures LLC, as administrative agent, and the lenders party thereto (effective 2022-10-25).","evidence_excerpt":"On October 25, 2022, Corbus Pharmaceuticals Holdings, Inc. (the “ Company ”) entered into an amendment to the Loan and Security Agreement (the “ Loan Agreement ” and the amendment, the “ Amended Loan Agreement ”), dated as of July 28, 2020, with its subsidiary, Corbus Pharmaceuticals, Inc. as borrower, the Company as guarantor, each lender party thereto (the “ Lenders ”), K2 HealthVentures LLC, as administrative agent for the Lenders, and Ankura Trust Company, LLC, as collateral agent for the Lenders.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017022020636/0000950170-22-020636-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"K2 HealthVentures LLC, as administrative agent, and the lenders party thereto"},{"label":"Effective","value":"2022-10-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}